Skip to content

Study · Not a test of the peptide alone · 2025

9 results

Protein to biomaterials: Unraveling the antiviral and proangiogenic activities of Ac-Tβ1-17 peptide, a thymosin β4 metabolite, and its implications in peptide-scaffold preparation.

Rahaman KA, Mukim MSI, Hasan ML, Kim H, Pan CH, Kwon OS, Song DG, Han HS

Bioactive materials19 Mar 2025Cited by 6 (Europe PMC)

PMID40177110 (opens in a new tab)PMCIDPMC11964602 (opens in a new tab)DOI10.1016/j.bioactmat.2025.02.008 (opens in a new tab)PepBankPUB-40177110
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 01LabNot a test of Thymosin beta-4 (human) aloneEx vivo tissueActivity measurement

    In ex vivo mouse fetal metatarsals, Ac-Tβ1-17 enhanced growth.

    In plain wordsIn lab-grown mouse bone tissue, a thymosin beta‑4 fragment increased growth.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseFetal metatarsal growth
    Study

    mousen: not reported in source

    fetal metatarsal
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Ac-Tβ1-17 peptide treatment showed similar results in ex vivo by enhancing mouse fetal metatarsal growth and angiogenesis.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 02LabNot a test of Thymosin beta-4 (human) aloneEx vivo tissueActivity measurement

    In ex vivo mouse fetal metatarsals, Ac-Tβ1-17 enhanced angiogenesis.

    In plain wordsIn lab-grown mouse bone tissue, a thymosin beta‑4 fragment increased new blood vessel formation.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseAngiogenesis in fetal metatarsal
    Study

    mousen: not reported in source

    fetal metatarsal
    Outcome group
    Wound healing · Musculoskeletal

    Source sentences

    Summary
    Ac-Tβ1-17 peptide treatment showed similar results in ex vivo by enhancing mouse fetal metatarsal growth and angiogenesis.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  3. 03LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Activity measurement

    In human umbilical vein endothelial cells, Ac-Tβ1-17 promoted cell proliferation.

    In plain wordsIn cells, a thymosin beta‑4 fragment increased cell growth.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseHUVEC cell proliferation
    Study

    humann: not reported in source

    HUVEC
    Outcome group
    Wound healing · Skin and wound

    Source sentences

    Summary
    Additionally, Ac-Tβ1-17 demonstrated beneficial effects, such as cell proliferation, wound healing, and scavenging of reactive oxygen species (ROS) in human umbilical vein endothelial cells (HUVEC).

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  4. 04LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Activity measurement

    In human umbilical vein endothelial cells, Ac-Tβ1-17 showed beneficial wound healing effects.

    In plain wordsIn cells, a thymosin beta‑4 fragment helped wound closure.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseHUVEC wound healing
    Study

    humann: not reported in source

    HUVEC
    Outcome group
    Wound healing · Skin and wound

    Source sentences

    Summary
    Additionally, Ac-Tβ1-17 demonstrated beneficial effects, such as cell proliferation, wound healing, and scavenging of reactive oxygen species (ROS) in human umbilical vein endothelial cells (HUVEC).

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  5. 05LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Activity measurement

    In human umbilical vein endothelial cells, Ac-Tβ1-17 scavenged reactive oxygen species.

    In plain wordsIn cells, a thymosin beta‑4 fragment cleared reactive oxygen species.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseReactive oxygen species scavenging
    Study

    humann: not reported in source

    HUVEC
    Outcome group
    Aging markers · Skin and wound

    Source sentences

    Summary
    Additionally, Ac-Tβ1-17 demonstrated beneficial effects, such as cell proliferation, wound healing, and scavenging of reactive oxygen species (ROS) in human umbilical vein endothelial cells (HUVEC).

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  6. 06LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Activity measurement

    A peptide-based scaffold containing Ac-Tβ1-17 facilitated cell growth and angiogenesis inside the scaffold.

    In plain wordsIn lab tests, a scaffold holding a thymosin beta‑4 fragment supported cell growth and new vessel formation.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseCell growth and angiogenesis in scaffold
    Study

    n: not reported in source

    peptide-based scaffold
    Outcome group
    Wound healing · Skin and wound

    Source sentences

    Summary
    Integrating Ac-Tβ1-17 into a peptide-based scaffold facilitated cell growth and angiogenesis inside the scaffold and through gradual release into the surrounding environment.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  7. 07LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    In HUVEC, Ac-Tβ1-17 treatment increased Akt, ERK, PI3K, MEK and Bcl-2 gene expression.

    In plain wordsIn cells, a thymosin beta‑4 fragment raised activity of genes in growth and survival pathways.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseAkt, ERK, PI3K, MEK and Bcl-2 gene expression
    Study

    humann: not reported in source

    HUVEC
    Outcome group
    Receptor activity and mechanism · Skin and wound

    Source sentences

    Summary
    The Ac-Tβ1-17 peptide treatment induced significant biochemical responses in HUVEC, increasing Akt, ERK, PI3K, MEK, and Bcl-2 gene expression and proangiogenic proteins.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  8. 08LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    In HUVEC, Ac-Tβ1-17 treatment increased proangiogenic proteins.

    In plain wordsIn cells, a thymosin beta‑4 fragment raised proteins that drive blood vessel growth.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseProangiogenic protein levels
    Study

    humann: not reported in source

    HUVEC
    Outcome group
    Receptor activity and mechanism · Skin and wound

    Source sentences

    Summary
    The Ac-Tβ1-17 peptide treatment induced significant biochemical responses in HUVEC, increasing Akt, ERK, PI3K, MEK, and Bcl-2 gene expression and proangiogenic proteins.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  9. 09LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Activity measurement

    Ac-Tβ1-17, a Tβ4 metabolite, showed significant protease inhibition against SARS-CoV-2, surpassing its precursor protein.

    In plain wordsIn lab tests, a fragment of thymosin beta‑4 blocked a SARS-CoV-2 enzyme more than the whole protein did.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseSARS-CoV-2 protease inhibition
    Study

    n: not reported in source

    Comparator
    Tβ4 precursor protein
    Outcome group
    Antiviral activity · Infection

    Source sentences

    Summary
    This study found that the novel peptide metabolite acetyl-thymosin β4 (amino acid 1-17) (Ac-Tβ1-17) exhibited significant protease inhibition activity against SARS-CoV-2, surpassing its precursor protein.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.